Middletown, DE -- (SBWIRE) -- 09/23/2013 -- VipStockReports.com screens the markets looking for Hot Emerging Micro-cap and Small cap stocks that look to Run High. Our team STRONGLY believes the penny stock market can powerfully reward average traders, and we are here to lead the way. Today our focus is on: Celsion Corporation (NASDAQ:CLSN), PDL BioPharma Inc. (NASDAQ:PDLI), Idenix Pharmaceuticals Inc (NASDAQ:IDIX), Nektar Therapeutics (NASDAQ:NKTR).
Celsion Corporation (NASDAQ:CLSN) ended its recent business day with the gain of 2.52% and closed at the price of $1.22 after opening at $1.19. The stock traded during its last trading session with the total volume of 1.85 million shares, as compared to its average volume of 1.93 million shares. Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology.
For How Long CLSN will Fight for Profitability? Read This Trend Analysis report
PDL BioPharma Inc. (NASDAQ:PDLI) stock traded during its last trading session with the total traded volume of 1.87 million shares versus its average volume of 1.55 million shares. The company opened its trade at the price of $8.07 and its closing price was $8.05 after losing -0.43% for the day. PDL BioPharma, Inc. engages in intellectual property asset management and patent portfolio and related assets investment activities. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases, as well as other medical conditions.
Has PDLI Found The Bottom And Ready To Gain Momentum? Find Out Here
Idenix Pharmaceuticals Inc (NASDAQ:IDIX) traded on volume of 2.41 million shares in the last session against average volume of 914,500.00 shares. The company started its trading session with the price of $5.69 and closed at $5.60 by scoring -1.58%. Idenix Pharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, engages in the discovery and development of drugs for the treatment of human viral diseases in the United States and France.
Why Should Investors Buy IDIX After the Recent Fall? Just Go Here and Find Out
Nektar Therapeutics (NASDAQ:NKTR) showed 2.16 million shares in volume during the last trading session, while the average trading volume remained 1.17 million shares. The stock kicked off its trading session at $13.83 and closed at $13.96 after mounting 1.16%.
Why Should Investors Buy NKTR After The Recent Gain? Just Go Here and Find Out
We screen the markets looking for Hot Emerging Micro-cap and Small cap stocks that look to Run High. Once we find the 'Next Hot Penny Stock' with Monster Upside Potential we immediately Email it to you in our detailed VIP Report so you can Beat Rest of the Crowd!!
Our team STRONGLY believes the penny stock market can powerfully reward average traders, and we are here to lead the way.
VipstockReports.com newsletters and website: The disclaimer is to be read entirely and fully understood before using our website, or joining our newsletter email list. Never invest into a stock discussed on this website or the Vipstockalerts.com newsletter unless you can afford to lose your entire investment. Please consult with a certified financial advisor before making any investment decisions.
VipStockReports.com and any affiliates and information providers make no implied or express warranties on the information provided. Please verify quotes with your financial advisor before making investment decisions. This is not to be construed as a solicitation to buy or sell securities. As with any stock, the featured companies profiled on the VipstockReports.com web site and/or newsletter involve a high degree of volatility and risk, and all investors should know that they may lose a portion of or all of their investment if they decide to purchase any stocks.
Read Full Disclaimer at: http://www.vipstockreports.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)